At present, numerous studies are being conducted on inhibitors of complement components (such as C1, C3, C5, and C5aR1), and the inhibition of pathological complement activation has emerged as a potential therapy to prevent DKD progression. This evidence concerns the gene C5 and diabetic kidney disease.